» Articles » PMID: 30674078

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

Overview
Date 2019 Jan 24
PMID 30674078
Citations 123
Authors
Affiliations
Soon will be listed here.
Abstract

Meta-analyses conducted >15 years ago reported that improvements in bone mineral density (BMD) were associated with reduction in vertebral and nonvertebral fractures in osteoporosis trials. Numerous studies have been conducted since then, incorporating new therapies with different mechanisms of action and enrolling many more subjects. To extend these prior analyses, we conducted a meta-regression of 38 placebo-controlled trials of 19 therapeutic agents to determine the association between improvements in BMD and reductions in fracture risk. We used a linear model to examine the relationship between mean percent difference in BMD change between treatment and placebo groups and the logarithm of the relative risk. We found that greater improvements in BMD were strongly associated with greater reductions in vertebral and hip fractures but not nonvertebral fractures. For vertebral fracture, the r values for total hip, femoral neck, and lumbar spine BMD change were 0.56, 0.54, and 0.63, respectively (p ≤ 0.0002). For a 2% or 6% improvement in total hip BMD, we might expect a 28% or 66% reduction, respectively, in vertebral fracture risk. For hip fracture, the r values for total hip, femoral neck, and lumbar spine BMD change were 0.48 (p = 0.01), 0.42 (p = 0.02), and 0.22 (ns), respectively. For a 2% or 6% improvement in total hip BMD, we might expect a 16% or 40% reduction in hip fracture risk. In conclusion, our results extend prior observations that larger improvements in dual-energy X-ray absorptiometry (DXA)-based BMD are associated with greater reductions in fracture risk, particularly for vertebral and hip fractures. Although these results cannot be directly applied to predict the treatment benefit in an individual patient, they provide compelling evidence that improvements in BMD with osteoporosis therapies may be useful surrogate endpoints for fracture in trials of new therapeutic agents. © 2019 American Society for Bone and Mineral Research.

Citing Articles

Five-year evaluation of bone health in liver transplant patients: developing a risk score for predicting bone fragility progression beyond the first year.

Abate E, McKenna A, Yang L, Ball C, Kearns A Front Endocrinol (Lausanne). 2025; 16:1467825.

PMID: 40052155 PMC: 11882866. DOI: 10.3389/fendo.2025.1467825.


Biomechanics of a Drop Landing: Osteogenic Stimulus Measures May Vary.

Wilzman A, Wong D, Troy K J Musculoskelet Neuronal Interact. 2025; 25(1):1-17.

PMID: 40024223 PMC: 11880855. DOI: 10.22540/JMNI-25-001.


Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico.

Diaz Martinez J, Aubry de Maraumont T, Natty Sanchez E, Camacho Cordero L, Yeh E PLoS One. 2025; 20(2):e0299673.

PMID: 39919094 PMC: 11805434. DOI: 10.1371/journal.pone.0299673.


Similarities in distribution pattern between acute multiple osteoporotic vertebral compression fractures and vertebral fractures cascades.

Wang F, Sun R, Zhang S, Wu X J Orthop Surg Res. 2024; 19(1):844.

PMID: 39696524 PMC: 11657487. DOI: 10.1186/s13018-024-05337-z.


Automated bone property analysis using corrected in vivo dental cone-beam CT data of human wrists.

Klintstrom B, Spangeus A, Malusek A, Synek A, Woisetschlager M, Pahr D Sci Rep. 2024; 14(1):30466.

PMID: 39681574 PMC: 11649766. DOI: 10.1038/s41598-024-75222-6.